Printer Friendly

MILES INC. AND ICI PHARMACEUTICALS GROUP ANNOUNCE CO-PROMOTION AGREEMENT TO SELL CIPRO

MILES INC. AND ICI PHARMACEUTICALS GROUP ANNOUNCE CO-PROMOTION AGREEMENT TO
 SELL CIPRO
 WEST HAVEN, Conn., Sept. 30 /PRNewswire/ -- Miles Inc.'s Cipro (ciprofloxacin) tablets, the number one selling quinolone anti-microbial therapy, will be supported by an additional 400 person sales force from ICI Pharmaceuticals Group of Wilmington, Del., beginning this fall, according to a joint announcement from the two companies today.
 The product will be detailed by ICI Pharmaceuticals Group's ICI Pharma medical representatives to primary care physicians and ICI Pharma specialty representatives to urologists. The ICI sales force supplements the 1,200 person Miles Inc. Pharmaceutical Division sales organization. Cipro was launched by Miles in 1987. Over 30 million patients have been treated with Cipro in the U.S. and over 80 million have been treated worldwide.
 Miles is providing assistance to ICI in the training of its representatives. Financial and other terms of the agreement were not disclosed.
 "This agreement allows ICI to build on our long-term commitment to the therapeutic area of anti-infectives and capitalize on the respected position the company has built with primary care physicians with antihypertensive products such as Tenormin(R) (atenolol) and Zestril(R) (lisinopril)," said Jack Duncan, vice president for sales and marketing at ICI.
 ICI Pharmaceuticals Group, which includes ICI Pharma and Stuart Pharmaceuticals, is a business unit of ICI Americas Inc., the U.S. subsidiary of U.K.-based Imperial Chemical Industries PLC. In the 50 years since the company was founded, ICI has earned an outstanding reputation as an innovative, research-intensive company dedicated to pharmaceutical discovery, development and production. ICI Pharmaceuticals Group has approximately 3,000 employees, including some 800 of whom are engaged in research, development and quality assurance, and a sales force of 1,000 representatives.
 "Cipro has become a highly respected therapy among infectious disease specialists, urologists, internists and other specialists. This new partnership will help increase important prescribing knowledge among primary care physicians and bring significant benefits to their patients," said Gerald Rosenberg, senior vice president for sales and marketing for Miles Inc., Pharmaceutical Division.
 Miles Inc. is a Fortune 100, research-based company with major businesses in chemicals, health care and imaging technologies. Headquartered in Pittsburgh, Miles employs some 26,000 people at its operations throughout North America. In 1991, the company's sales were $6.2 billion. The Pharmaceutical Division of Miles Inc., which markets anti-microbials, such as Cipro and Cipro I.V., allergy products and biologicals, such as Gamimune - N intravenous immunoglobulin, is one of eight operating divisions. The Pharmaceutical Division is based in West Haven, Conn.
 -0- 09/30/92
 CONTACT: Donald Hyman of Miles Inc., 203-498-6545, or Mark Sahl of ICI Pharmaceuticals Group, 302-886-7859 CO: MILES INC.; ICI PHARMACEUTICALS IN: MTC ST: CT,PA,DE -- NY043 -- X548 09/30/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1992
Words:458
Previous Article:BIG BEAR TO ACQUIRE FIVE STORES IN OHIO
Next Article:VLASIC FOODS TO CLOSE PLANT IN CALIFORNIA
Topics:


Related Articles
ABBOTT LABORATORIES INTRODUCES NEW QUINOLONE ANTIBIOTIC
MEDI-PHYSICS/AMERSHAM HEALTHCARE AND ZENECA PHARMACEUTICALS SET CO-PROMOTION AGREEMENT FOR CANCER PAIN THERAPY AGENT
PHARMACEUTICAL RESOURCES TO DISTRIBUTE TRIAZOLAM; FOR ALPHAPHARM; ATENOLOL FOR GENPHARM
PHARMACEUTICAL RESOURCES SIGNS DISTRIBUTION AGREEMENT WITH MOVA FOR TWO PRODUCTS
PHARMACEUTICAL RESOURCES SIGNS DISTRIBUTION AGREEMENT WITH MOVA FOR TWO PRODUCTS
MARION MERRELL DOW INC. TO CO-PROMOTE PRILOSEC(R) WITH ASTRA MERCK INC. IN THE UNITED STATES
DURA PHARMACEUTICALS SIGNS AGREEMENT WITH BAUSCH & LOMB PHARMACEUTICALS TO CO-PROMOTE OPHTHALMIC ALLERGY DRUG
FOREST LABORATORIES AND MURO PHARMACEUTICAL ENTER CO-PROMOTION AGREEMENT FOR AEROBID AND VOLMAX
DURA PHARMACEUTICALS SIGNS AGREEMENT TO CO-PROMOTE A NEW RESPIRATORY DRUG WITH KEY PHARMACEUTICALS
ALZA and Bayer Announce Two U.S. Co-Promotion Agreements.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters